Monday, July 6, 2026

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), HSBC Holdings plc (HSBC) and Palantir Technologies Inc. (PLTR), as well a micro-cap stock CBL & Associates Properties, Inc. (CBL). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> Pre-Markets Muted Ahead of (Expected) Quiet Week

Today's Featured Research Reports

Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+58.2% vs. +39.7%). Demand for the company’s popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company’s key top-line drivers. Lilly’s other new drugs like Kisunla, Omvoh and Jaypirca are also contributing to top-line growth. 

Eli Lilly is also making rapid progress in its pipeline with its new oral GLP-1 obesity pill, Foundayo, expected to be a commercial game-changer for Lilly. Lilly has aggressively expanded through M&A in 2026 across oncology, neuroscience, cardiovascular and other areas to diversify growth beyond GLP-1 therapies. 

Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 market are some top-line headwinds. Estimates have declined slightly ahead of Q2 results. Lilly has a positive record of earnings surprises in recent quarters.

(You can read the full research report on Eli Lilly here >>>)

Shares of HSBC have outperformed the Zacks Banks - Foreign industry over the past year (+69.1% vs. +43%). The company’s wealth momentum in Asia continues to benefit from higher customer activity, rising balances and net new money, while the completed Hang Seng Bank privatization and ongoing business divestitures, including the planned Indonesia business sale, will simplify operations and support medium-term efficiency. 

Further, a robust capital position and global footprint are expected to support its financials. However, the company has guided for higher expected credit losses (ECL) this year because of overlays tied to Middle East events and absorption of an idiosyncratic fraud-related charge. 

Moreover, operating expenses are expected to remain elevated as the company invests in technology and distribution capabilities. Revenue visibility will depend on volatile rates and activity.

(You can read the full research report on HSBC here >>>)

Palantir’s shares have declined -5.8% over the past year against the Zacks Internet - Software industry’s decline of -18%. The company’s AI strategy, driven by Foundry, Gotham, and AIP platforms, targets government and commercial sectors, enabling real-time insights and operational efficiency. 

Notable defense projects, like Open DAGIR and AIP boot camps for commercial clients, boost customer acquisition. With $7.2 billion in cash, no debt, and S&P 500 inclusion, Palantir enjoys strong liquidity, growing revenues, and increased investor visibility. 

Meanwhile, PLTR's reluctance to pay dividends is a red flag for dividend-seeking investors. Intense competition from tech giants and declining cost flexibility as the company scales are notable headwinds.

(You can read the full research report on Palantir here >>>)

Shares of CBL & Associates Properties have outperformed the Zacks REIT and Equity Trust - Retail industry over the past year (+119.3% vs. +28.3%). This microcap company with a market capitalization of $1.63 billion, is strengthening its investment case through stable operating trends, disciplined capital allocation and a focus on high-quality, market-dominant retail assets. 

Capital recycling, refinancing and redevelopment initiatives are enhancing portfolio quality, improving financial flexibility and supporting sustainable cash flow growth, while a conservative dividend policy supports shareholder returns. 

However, the investment thesis remains balanced by modest organic NOI growth, tenant turnover, limited renewal pricing power, redevelopment execution risks and continued asset-level stress within weaker properties. The valuation suggests investors are assigning limited value to CBL’s long-term cash flow improvement potential and portfolio optimization efforts, leaving scope for upside if management continues to execute and operating performance strengthens.

(You can read the full research report on CBL & Associates Properties here >>>)

Other noteworthy reports we are featuring today include Enterprise Products Partners L.P. (EPD), Flex Ltd. (FLEX) and UDR, Inc. (UDR).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>